GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Cyclically Adjusted Revenue per Share

Neurobiological Technologies (Neurobiological Technologies) Cyclically Adjusted Revenue per Share : $0.00 (As of Sep. 2009)


View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Neurobiological Technologies's adjusted revenue per share for the three months ended in Sep. 2009 was $0.224. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2009.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-07), Neurobiological Technologies's current stock price is $0.0001. Neurobiological Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2009 was $0.00. Neurobiological Technologies's Cyclically Adjusted PS Ratio of today is .


Neurobiological Technologies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Neurobiological Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies Cyclically Adjusted Revenue per Share Chart

Neurobiological Technologies Annual Data
Trend Jun00 Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neurobiological Technologies Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neurobiological Technologies's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Neurobiological Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurobiological Technologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's Cyclically Adjusted PS Ratio falls into.



Neurobiological Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neurobiological Technologies's adjusted Revenue per Share data for the three months ended in Sep. 2009 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2009 (Change)*Current CPI (Sep. 2009)
=0.224/91.1196*91.1196
=0.224

Current CPI (Sep. 2009) = 91.1196.

Neurobiological Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
199912 0.000 71.008 0.000
200003 0.000 72.231 0.000
200006 0.000 72.737 0.000
200009 0.000 73.286 0.000
200012 0.818 73.413 1.015
200103 0.000 74.341 0.000
200106 0.773 75.100 0.938
200109 0.000 75.227 0.000
200112 0.000 74.552 0.000
200203 0.000 75.438 0.000
200206 0.000 75.902 0.000
200209 0.496 76.366 0.592
200212 0.000 76.324 0.000
200303 0.099 77.716 0.116
200306 0.103 77.505 0.121
200309 0.004 78.138 0.005
200312 0.109 77.758 0.128
200403 0.682 79.066 0.786
200406 0.051 80.037 0.058
200409 0.144 80.121 0.164
200412 0.181 80.290 0.205
200503 0.198 81.555 0.221
200506 0.290 82.062 0.322
200509 0.272 83.876 0.295
200512 0.588 83.032 0.645
200603 1.093 84.298 1.181
200606 0.969 85.606 1.031
200609 1.132 85.606 1.205
200612 0.952 85.142 1.019
200703 1.151 86.640 1.211
200706 0.856 87.906 0.887
200709 0.817 87.964 0.846
200712 0.190 88.616 0.195
200803 0.137 90.090 0.139
200806 0.131 92.320 0.129
200809 0.132 92.307 0.130
200812 0.130 88.697 0.134
200903 0.112 89.744 0.114
200906 0.603 91.003 0.604
200909 0.224 91.120 0.224

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Neurobiological Technologies  (OTCPK:NTII) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Neurobiological Technologies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurobiological Technologies (Neurobiological Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
Ariel Warszawski 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp 10 percent owner 426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp 10 percent owner FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin director
Abraham E Cohen director 500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer director HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc other: Direct Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines